Details for Patent: 11,234,946
✉ Email this page to a colleague
Which drugs does patent 11,234,946 protect, and when does it expire?
Patent 11,234,946 protects AUVELITY and is included in one NDA.
This patent has two hundred and fourteen patent family members in thirty-three countries.
Summary for Patent: 11,234,946
| Title: | Bupropion as a modulator of drug activity |
| Abstract: | Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. |
| Inventor(s): | Herriot Tabuteau |
| Assignee: | Antecip Bioventures II LLC |
| Application Number: | US17/092,968 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 11,234,946
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-001 | Aug 18, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-001 | Aug 18, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE BY INCREASING DEXTROMETHORPHAN PLASMA LEVELS IN NON-POOR METABOLIZERS OF DEXTROMETHORPHAN | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,234,946
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014346807 | ⤷ Start Trial | |||
| Australia | 2015350559 | ⤷ Start Trial | |||
| Australia | 2018203638 | ⤷ Start Trial | |||
| Australia | 2019201548 | ⤷ Start Trial | |||
| Australia | 2019223187 | ⤷ Start Trial | |||
| Australia | 2019236614 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
